Impact of race and baseline PSA on longitudinal PSA

International Journal of Cancer

Volumn 118, Issue 7, 2006, Pages 1773-1776

  McGreevy, Katharine ^a,b   Rodgers, Keith ^a   Lipsitz, Stuart ^a,c   Bissada, Nabil ^d   Hoel, David ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Prostate cancer screening; Prostate specific antigen (PSA); Race

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER SCREENING; CAUCASIAN; FAMILY HISTORY; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; RACE; RACE DIFFERENCE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; EUROPEAN CONTINENTAL ANCESTRY GROUP; HUMANS; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REFERENCE VALUES; TIME FACTORS;

EID: 33644849701     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21553     Document Type: Article

References (37)

1. Society AC. CFF: Cancer facts and Figures 2001: American Cancer Society Surveillance Research, 2001.
2. Grossfeld GD, Carroll PR. Prostate cancer early detection: a clinical perspective. [Review; 91 references therein]. Epidemiol Rev 2001; 23(1):173-80.
3. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993;270(8):948-54.
4. Richardson TD, Oesterling JE. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am 1997;24:339-51.
5. Barry MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer. [Review; 37 references therein]. N Engl J Med 2001;344:1373-77.
6. Signorello LB, Adami HO. Prostate cancer. In: Adami HO, Hunter D, Trichopoulos D, eds. Textbook of cancer epidemiology. New York: Oxford University Press, 2002,400-28.
7. Fowler JE, Jr, Bin L, Collins MM, Roberts RG, Oesterling JE, Wasson JH. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med 1998;104:526-32.
8. AUA. Prostate-specific antigen (PSA) best practice policy. Am Urol Assoc 2000;14:267-86.
9. Smith RA, Cokkinides V, von Eschenbach AC, Levin B, Cohen C, Runowicz CD. American Cancer Society Guidelines for the early detection of cancer. CA Cancer J Clin 2002;52:8-22.
10. Ross KS, Carter HB, Pearson JD, Guess HA. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA 2000;284(11):1399-405.
11. Etzioni R, Cha R, Cowen ME. Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies. J Urol 1999;162:741-48.
12. Harris RP, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. preventive services task force. Ann Inter Med 2002;137:917-29.
13. Cooney KA, Strawderman MS, Wojno KJ, Doerr KM, Taylor A, Alcser KH, Heeringa SG, Taylor JM, Wei JT, Montie JE, Schottenfeld D. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. [Review; 20 references therein]. Urology 2001;57(1):91-96.
14. Weinrich MC, Jacobsen SJ, Weinrich SP, Moul JW, Oesterling JE, Jacobson D, Wise R. Reference ranges for serum prostate-specific antigen in black and white men without cancer. Urology 1998;52(6): 967-73. Available at http://www.sciencedirect.com/science/article/B6VJW-3WDDGNS-4/1/ ea676c4c91ee8e9e81cb602a90b47e80.
15. Morgan TO, Jacobsen SJ, McCarthy WF, Jacobson DJ, McLeod DG, Moul JW. Age-specific reference ranges for serum prostate-specific antigen in black men. N Engl J Med 1996;335(5):304-10. Available at http://content.nejm.org/cgi/ content/abstract/335/5/304.
16. Eastham JA, Sartor O, Richey W, Moparty B, Sullivan J. Racial variation in prostate specific antigen in a large cohort of men without prostate cancer. J La State Med Soc 2001;153(4):184-89.
17. DeAntoni EP, Crawford ED, Oesterling JE, Ross CA, Berger ER, McLeod DG, Staggers F, Stone NN. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 1996;48(2):234-39. Available at http://www.sciencedirect.com/science/article/ B6VJW-4287KTX-P1/1/75d8416e43a38e65c6afdb1eff0c750d.
18. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. [see comments.]. JAMA 1993;270(7):860-64.
19. Oesterling JE, Kumamoto Y, Tsukamoto T, Girman CJ, Guess HA, Masumori N, Jacobsen SJ, Lieber MM. Serum prostate-specific antigen in a community-based population of healthy Japanese men: lower values than for similarly aged white men. Br J Urol 1995;75(3):347-53.
20. Moul JW, Sesterhenn IA, Connelly RR, Douglas T, Srivastava S, Mostofi FK. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 1995;274:1277-81.
21. Vijayakumar S, Karrison T, Weichselbaum RR, Chan S, Quadri SF, Awan AM. Racial differences in prostate-specific antigen levels in patients with local-regional prostate cancer. Cancer Epidemiol Biomarkers Prev 1992;1:541-45.
22. SAS. ed. Version 8. Cary NC: The SAS Institute, 1999.
23. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS system for mixed models. Cary: SAS Institute Inc., 1996.
24. Lin H, McCulloch CE, Turnbull BW, Slate EH, Clark LC. A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations. Stat Med 2000;19:1303-18.
25. Pearson JD, Morrell CH, Landis PK, Carter HB, Brant LJ. Mixed-effects regression models for studying the natural history of prostate disease. Stat Med 1994;13:587-601.
26. Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 1995;87(5):354-60.
27. Laird NM. Missing data in longitudinal studies. Stat Med 1988;7:305-15.
28. Lipsitz SR, Fitzmaurice GM, Ibrahim JG, Gelber R, Lipshultz S. Parameter estimation in longitudinal studies with outcome-dependent follow-up. Biometrics 2002;58:621-30.
29. Crawford D: PSA changes as related to the initial PSA: Data from the prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial. Am Soc Clin Oncol 2002.
30. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997;277(18):1456-60.
31. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol 2003;169(5):1720-23.
32. Ito K, Yamamoto K, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Cumulative probability of PSA increase above 4.0 ng/mL in population-based screening for prostate cancer. Int J Cancer 2004; 109:455-60.
33. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer. Urol Clin North Am 1993;4:665-70.
34. Ito K, Yamamoto T, Suzuki K, Kurokawa K, Yamanaka H The risk of rapid prostate specific antigen increase in men with baseline prostate specific antigen 2.0 ng/ml or less. J Urol 2004;171(2 Pt 1):656-60.
35. Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schroder FH. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening. Cancer 2005;103(2): 242-50.
36. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford D, Crowley JJ, Coltman CA, Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤ 4.0 ng per milliliter. N Engl J Med 2004;350(22):2239-46.
37. Ito K, Yamamoto T, Ohi M, Takechi H, Kurokawa K, Suzuki K, Yamanaka H. Natural history of PSA increase with and without prostate cancer. Urology 2003;62(1):64-9.